Compare these realistic paths consistently
These paths are not ranked. Use the same factors for each option that remains realistic after clinical review.
Are camouflage or no active treatment legitimate choices?
Yes. You may use camouflage, cosmetics, self-tanning products, clothing, or no concealment; you may also choose no active medical treatment. These choices can change over time and do not mean you have given up.
Patient and clinical guidance recognize appearance support, psychosocial support, and choosing not to pursue repigmentation. You can still seek diagnosis, skin protection guidance, emotional support, and a plan for future changes.
Individual products differ in ingredients, finish, sensitivity, and cost. Choosing no active treatment does not predict that vitiligo will remain unchanged.
Compare the time, follow-up, daily effort, and practical burden of this exact path.
Confirm current availability, qualified support, coverage, and personal cost before relying on this path.
Ask what can be stopped or revisited and which outcomes remain uncertain.
When might a surgical or cell-based procedure be discussed?
Procedures may be discussed for carefully selected people whose vitiligo is judged clinically stable, often after other paths have not met the goal. Stability, body site, healing, access, specialist experience, and expectations all matter.
Guidelines and systematic reviews describe grafting and cell-transfer approaches for selected stable vitiligo. In the United States, one cell-harvesting system has a defined vitiligo authorization for selected adults in trained settings.
“Stable” is a clinical judgment, not a self-test. Evidence is often nonrandomized, and eligibility for one procedure does not establish eligibility for another.
Compare the time, follow-up, daily effort, and practical burden of this exact path.
Confirm current availability, qualified support, coverage, and personal cost before relying on this path.
Ask what can be stopped or revisited and which outcomes remain uncertain.
What outcomes and harms should I understand before a procedure?
Ask about incomplete or uneven color return, mismatched color or texture, scarring, healing, and how long results may last. Also ask what support is available if the result misses your goal. A procedure cannot guarantee a lasting or even-looking result.
Published techniques and outcomes vary, as do study quality and adverse-effect reporting. Body site and operator experience can affect what is realistic.
Average study results cannot predict your color match, satisfaction, healing, or relapse. Costs and coverage may be uncertain.
Compare the time, follow-up, daily effort, and practical burden of this exact path.
Confirm current availability, qualified support, coverage, and personal cost before relying on this path.
Ask what can be stopped or revisited and which outcomes remain uncertain.
What is depigmentation therapy?
Depigmentation is a specialist path that reduces remaining color for selected people with extensive vitiligo. It is not a routine cosmetic shortcut. The change may be permanent and may create lifelong sun-sensitivity concerns. It requires careful medical and mental-health discussion.
International guidance includes depigmentation among selected management strategies rather than placing it on a universal treatment ladder. The goal is different from repigmentation.
Suitability, access, product status, outcome, and reversibility vary by person and jurisdiction. Any named product needs its own evidence, status, and clinical instructions.
Compare the time, follow-up, daily effort, and practical burden of this exact path.
Confirm current availability, qualified support, coverage, and personal cost before relying on this path.
Ask what can be stopped or revisited and which outcomes remain uncertain.
Are camouflage or no active treatment legitimate choices?
Yes. You may use camouflage, cosmetics, self-tanning products, clothing, or no concealment; you may also choose no active medical treatment. These choices can change over time and do not mean you have given up. Evidence Evidence
Why this matters
- Sources cited, not yet graded
Patient and clinical guidance recognize appearance support, psychosocial support, and choosing not to pursue repigmentation. You can still seek diagnosis, skin protection guidance, emotional support, and a plan for future changes.
Considerations
- Depends on you
Individual products differ in ingredients, finish, sensitivity, and cost. Choosing no active treatment does not predict that vitiligo will remain unchanged.
Questions for your clinician or a support professional
If I choose no active treatment, what changes should I keep track of?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Where can I find camouflage help without pressure to conceal?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
When might a surgical or cell-based procedure be discussed?
Procedures may be discussed for carefully selected people whose vitiligo is judged clinically stable, often after other paths have not met the goal. Stability, body site, healing, access, specialist experience, and expectations all matter. Evidence Evidence
Why this matters
- Sources cited, not yet graded
Guidelines and systematic reviews describe grafting and cell-transfer approaches for selected stable vitiligo. In the United States, one cell-harvesting system has a defined vitiligo authorization for selected adults in trained settings.
Considerations
- Depends on you
“Stable” is a clinical judgment, not a self-test. Evidence is often nonrandomized, and eligibility for one procedure does not establish eligibility for another.
Questions for your clinician or a support professional
How did you determine that my vitiligo is stable enough for this procedure?
Saving keeps this on your device and needs JavaScript, which is off in this browser.How often do you perform this exact technique on this body area?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What outcomes and harms should I understand before a procedure?
Ask about incomplete or uneven color return, mismatched color or texture, scarring, healing, and how long results may last. Also ask what support is available if the result misses your goal. A procedure cannot guarantee a lasting or even-looking result. Evidence Evidence
Why this matters
- Sources cited, not yet graded
Published techniques and outcomes vary, as do study quality and adverse-effect reporting. Body site and operator experience can affect what is realistic.
Considerations
- Depends on you
Average study results cannot predict your color match, satisfaction, healing, or relapse. Costs and coverage may be uncertain.
Questions for your clinician or a support professional
What outcomes are supported by evidence for people like me?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What happens if healing or repigmentation is incomplete?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What is depigmentation therapy?
Depigmentation is a specialist path that reduces remaining color for selected people with extensive vitiligo. It is not a routine cosmetic shortcut. The change may be permanent and may create lifelong sun-sensitivity concerns. It requires careful medical and mental-health discussion. Evidence Evidence Evidence
Why this matters
- Sources cited, not yet graded
International guidance includes depigmentation among selected management strategies rather than placing it on a universal treatment ladder. The goal is different from repigmentation.
Considerations
- Depends on you
Suitability, access, product status, outcome, and reversibility vary by person and jurisdiction. Any named product needs its own evidence, status, and clinical instructions.
Questions for your clinician or a support professional
Why is depigmentation being considered for me?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Which permanent changes and skin-protection needs matter?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Applicability check
Who was studied?
These fields show what the cited evidence reports about the people and body sites behind outcome or safety claims. “Not reported” means the reviewed source omitted the field; “Pending exact source review” means SteadySkin has not made that determination yet.
Ask about incomplete or uneven color return, mismatched color or texture, scarring, healing, and how long results may last. Also ask what support is available if the result misses your goal. A procedure cannot guarantee a lasting or even-looking result.
- Age range
- Pending exact source review
- Condition subtype
- Pending exact source review
- Severity or extent
- Pending exact source review
- Sample size
- Pending exact source review
- Geography and care setting
- Pending exact source review
- Skin tone or phototype
- Pending exact source review
- Race
- Pending exact source review
- Ethnicity
- Pending exact source review
- Body sites
- Pending exact source review
What that means for this page: This is explicitly gated as a group-level outcome claim, but exact population extraction is still pending. It cannot publish or support an individual prediction until that review is complete.
Depigmentation is a specialist path that reduces remaining color for selected people with extensive vitiligo. It is not a routine cosmetic shortcut. The change may be permanent and may create lifelong sun-sensitivity concerns. It requires careful medical and mental-health discussion.
- Age range
- Pending exact source review
- Condition subtype
- Pending exact source review
- Severity or extent
- Pending exact source review
- Sample size
- Pending exact source review
- Geography and care setting
- Pending exact source review
- Skin tone or phototype
- Pending exact source review
- Race
- Pending exact source review
- Ethnicity
- Pending exact source review
- Body sites
- Pending exact source review
What that means for this page: This is explicitly gated as a safety claim, but exact population extraction is still pending. It cannot publish or support an estimate of individual risk until that review is complete.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- Journal of the European Academy of Dermatology and VenereologyGuideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
Supports an expert-consensus map of established, off-label and developing Vitiligo treatment categories and makes clear that research is continuing.
What it does not support
It is an international consensus with extensive author relationships, not independent comparative proof, current U.S. regulatory status for every option or a personal treatment sequence.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- U.S. Food and Drug AdministrationRegulatory · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports FDA authorization of this device for repigmentation of stable depigmented vitiligo lesions in a defined adult population and trained professional setting.
What it does not support
It does not approve every grafting procedure, define stability for a reader or guarantee color match, durability or satisfaction.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- JAMA Dermatology (Ju HJ, et al.)Systematic review · Clinical research, tier 2Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that multiple surgical techniques have been studied for selected stable vitiligo and that reported response and adverse effects vary by method and study.
What it does not support
Much of the evidence is nonrandomized and an author reported industry relationships; the review does not determine stability, eligibility, color match, durability or individual outcome.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- U.S. Food and Drug AdministrationRegulatory · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The product company authored the prescribing information hosted by FDA. It is authoritative for the historical label but not independent clinical evidence.
What this source supports
Supports the historical US indication for final depigmentation in extensive disseminated idiopathic vitiligo, the purpose and mechanism limits, permanence and distant-depigmentation warnings, listed reactions, contraindication boundary, and long-term unknowns. Re-read in full on 2026-08-21 for what it states about sun, which is in three places. Under Precautions, General, it states that following therapy with the cream the skin will be sensitive for the rest of the patient’s life, and that the person must use sunscreens during exposure to the sun. Under Clinical Pharmacology it states that exposure to sunlight reduces the depigmenting effect of the drug. The same section states that the histology of the skin after depigmentation with topical monobenzone is the same as that seen in vitiligo, the epidermis being normal except for the absence of identifiable melanocytes. Under Dosage and Administration it states that prolonged exposure to sunlight should be avoided during treatment, or that a sunscreen should be used. Under Carcinogenesis, mutagenesis, impairment of fertility it states that no long term studies have been performed to evaluate carcinogenic potential.
What it does not support
The archived label does not establish current commercial availability, approval of a compounded preparation, predictable uniform results, suitability, a personal plan, or current status outside the US. Its sun statements are the label instructing a patient under a prescriber; SteadySkin reports them as the label’s wording and issues none of them as advice. It sets no sun protection factor, no interval and no exposure limit, and it measures nothing about how depigmented skin behaves in sunlight beyond the sensitivity statement itself. Because it performed no long term carcinogenicity study, it establishes nothing about skin cancer risk after depigmentation in either direction. The document carries a printed revision of August 2000 and an FDA banner stating it may not be the latest approved label, so it is used only for what it plainly states and never as current guidance.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- British Journal of Dermatology (Eleftheriadou V, et al.)Guideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence. Its classification table defines mucosal vitiligo as the oral or genital mucosae. One mucosal site alone is filed as undetermined or unclassified. Its differential diagnosis table lists genital or extragenital lichen sclerosus among the conditions that can be mistaken for vitiligo. That table also lists eczema, psoriasis, lichen planus, pityriasis alba and piebaldism. It calls autoimmunity a contributor to the pathogenesis of vitiligo. It reports an earlier review finding a possible negative impact on intimacy and sexual functioning. It tells clinicians to discuss the psychosocial impact of living with the condition. R28 offers a skin camouflage visit to people who want one. R10 to R14 name potent or very potent topical steroids as the first choice, with a topical calcineurin-inhibitor cream as an option for the face. These are different creams with different proof behind them. R20 names narrowband UVB as the first light option. It says the skin often does better on the face and trunk than on hands and feet. It says there is not enough proof to use any one current pill alone for vitiligo that is not changing. R25 and Table 2 keep cell grafting for vitiligo that is not changing and did not respond to other care. They also say a doctor cannot always tell if the vitiligo has truly stopped changing.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage. Its differential diagnosis table is a list, not a method a reader can apply to their own skin. It does not say how to tell any two of those conditions apart. It gives no figure for how often vitiligo affects genital skin.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Institute of Arthritis and Musculoskeletal and Skin DiseasesPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports a patient-facing description of clinician diagnosis using history and examination, possible use of a Wood lamp and selected tests, broad treatment categories, variable response and whole-person support.
What it does not support
It is educational context, not primary efficacy evidence, an online diagnostic method or a universal testing checklist.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports current US patient-language context that lighter patches have multiple causes, dermatologists diagnose vitiligo from history and examination, treatment is optional and several broad management paths exist.
What it does not support
The page acknowledges support from Incyte Dermatology, so it does not independently establish drug efficacy or comparative superiority.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.